A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Cell Cultures
2.2. Proliferation Assay
2.3. Western Blot Analysis
2.4. β-Arrestin 2 Silencing
2.5. Pertussis Toxin Pretreatment
2.6. PRL Secretion Assay
2.7. RT-PCR and Real-Time RT-PCR Analysis
2.8. Statistical Analysis
3. Results
3.1. DRD2-Biased Agonists’ Effects on Cell Proliferation and PRL Secretion in MMQ Cells
3.2. DRD2-Biased Agonists’ Effects on Cell Proliferation and PRL Secretion in Primary Cultured PRL-PitNET Cells
3.3. DRD2-Biased Agonists’ Effects on Cell Proliferation in Primary Cultured NF-PitNET Cells
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Melmed, S.; Casanueva, F.F.; Hoffman, A.R.; Kleinberg, D.L.; Montori, V.M.; Schlechte, J.A.; Wass, J.A.H. Endocrine Society. Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2011, 96, 273–288. [Google Scholar] [CrossRef] [PubMed]
- Greenman, Y.; Tordjman, K.; Osher, E.; Veshchev, I.; Shenkerman, G.; Reider-Groswasser, I.I.; Segev, Y.; Ouaknine, G.; Stern, N. Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth. Clin. Endocrinol. 2005, 63, 39–44. [Google Scholar] [CrossRef] [PubMed]
- Greenman, Y.; Cooper, O.; Yaish, I.; Robenshtok, E.; Sagiv, N.; Jonas-Kimchi, T.; Yuan, X.; Gertych, A.; Shimon, I.; Ram, Z.; et al. Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists. Eur. J. Endocrinol. 2016, 175, 63–72. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Colao, A.; Di Somma, C.; Pivonello, R.; Faggiano, A.; Lombardi, G.; Savastano, S. Medical therapy for clinically non-functioning pituitary adenomas. Endocr. Relat. Cancer 2008, 15, 905–915. [Google Scholar] [CrossRef]
- Cooper, O.; Greenman, Y. Dopamine Agonists for Pituitary Adenomas. Front. Endocrinol. 2018, 9, 469. [Google Scholar] [CrossRef] [Green Version]
- Even-Zohar, N.; Greenman, Y. Management of NFAs: Medical treatment. Pituitary 2018, 21, 168–175. [Google Scholar] [CrossRef]
- Peverelli, E.; Treppiedi, D.; Mangili, F.; Catalano, R.; Spada, A.; Mantovani, G. Drug resistance in pituitary tumours: From cell membrane to intracellular signalling. Nat. Rev. Endocrinol. 2021, 17, 560–571. [Google Scholar] [CrossRef]
- Sibley, D.R.; Monsma, F.J., Jr. Molecular biology of dopamine receptors. Trends Pharmacol. Sci. 1992, 13, 61–69. [Google Scholar] [CrossRef]
- Kim, K.M.; Valenzano, K.J.; Robinson, S.R.; Yao, W.D.; Barak, L.S.; Caron, M.G. Differential regulation of the dopamine D2 and D3 receptors by G protein-coupled receptor kinases and beta-arrestins. J. Biol. Chem. 2001, 276, 37409–37414. [Google Scholar] [CrossRef] [Green Version]
- Kim, S.J.; Kim, M.Y.; Lee, E.J.; Ahn, Y.S.; Baik, J.H. Distinct regulation of internalization and mitogen-activated protein kinase activation by two isoforms of the dopamine D2 receptor. Mol. Endocrinol. 2004, 18, 640–652. [Google Scholar] [CrossRef] [Green Version]
- Beaulieu, J.M.; Gainetdinov, R.R.; Caron, M.G. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol. Sci. 2007, 28, 166–172. [Google Scholar] [CrossRef] [PubMed]
- Mangili, F.; Giardino, E.; Treppiedi, D.; Barbieri, A.M.; Catalano, R.; Locatelli, M.; Lania, A.G.; Spada, A.; Arosio, M.; Mantovani, G.; et al. Beta-Arrestin 2 Is Required for Dopamine Receptor Type 2 Inhibitory Effects on AKT Phosphorylation and Cell Proliferation in Pituitary Tumors. Neuroendocrinology 2021, 111, 568–579. [Google Scholar] [CrossRef] [PubMed]
- Beaulieu, J.M.; Sotnikova, T.D.; Marion, S.; Lefkowitz, R.J.; Gainetdinov, R.R.; Caron, M.G. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005, 122, 261–273. [Google Scholar] [CrossRef] [Green Version]
- Vitali, E.; Peverelli, E.; Giardino, E.; Locatelli, M.; Lasio, G.B.; Beck-Peccoz, P.; Spada, A.; Lania, A.G.; Mantovani, G. Cyclic adenosine 3′-5′-monophosphate (cAMP) exerts proliferative and anti-proliferative effects in pituitary cells of different types by activating both cAMP-dependent protein kinase A (PKA) and exchange proteins directly activated by cAMP (Epac). Mol. Cell. Endocrinol. 2014, 383, 193–202. [Google Scholar] [CrossRef]
- Peverelli, E.; Mantovani, G.; Lania, A.G.; Spada, A. cAMP in the pituitary: An old messenger for multiple signals. J. Mol. Endocrinol. 2013, 52, R67–R77. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Urban, J.D.; Clarke, W.P.; von Zastrow, M.; Nichols, D.E.; Kobilka, B.; Weinstein, H.; Javitch, J.A.; Roth, B.L.; Christopoulos, A.; Sexton, P.M.; et al. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 2007, 320, 1–13. [Google Scholar] [CrossRef] [Green Version]
- Allen, J.A.; Yost, J.M.; Setola, V.; Chen, X.; Sassano, M.F.; Chen, M.; Peterson, S.; Yadav, P.N.; Huang, X.P.; Feng, B.; et al. Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc. Natl. Acad. Sci. USA 2011, 108, 18488–18493. [Google Scholar] [CrossRef] [Green Version]
- Free, R.B.; Chun, L.S.; Moritz, A.E.; Miller, B.N.; Doyle, T.B.; Conroy, J.L.; Padron, A.; Meade, J.A.; Xiao, J.; Hu, X.; et al. Discovery and characterization of a G protein-biased agonist that inhibits β-arrestin recruitment to the D2 dopamine receptor. Mol. Pharmacol. 2014, 86, 96–105. [Google Scholar] [CrossRef] [Green Version]
- Peverelli, E.; Giardino, E.; Treppiedi, D.; Meregalli, M.; Belicchi, M.; Vaira, V.; Corbetta, S.; Verdelli, C.; Verrua, E.; Serban, A.L.; et al. Dopamine receptor type 2 (DRD2) and somatostatin receptor type 2 (SSTR2) agonists are effective in inhibiting proliferation of progenitor/stem-like cells isolated from nonfunctioning pituitary tumors. Int. J. Cancer 2017, 140, 1870–1880. [Google Scholar] [CrossRef] [Green Version]
- Mangili, F.; Treppiedi, D.; Catalano, R.; Marra, G.; Di Muro, G.; Spada, A.; Arosio, M.; Peverelli, E.; Mantovani, G. A Novel Mechanism Regulating Dopamine Receptor Type 2 Signal Transduction in Pituitary Tumoral Cells: The Role of cAMP/PKA-Induced Filamin A Phosphorylation. Front. Endocrinol. 2021, 11, 611752. [Google Scholar] [CrossRef]
- Mangili, F.; Esposito, E.; Treppiedi, D.; Catalano, R.; Marra, G.; Di Muro, G.; Barbieri, A.M.; Locatelli, M.; Lania, A.G.; Mangone, A.; et al. DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells. Front. Endocrinol. 2022, 13, 867822. [Google Scholar] [CrossRef] [PubMed]
- Lopes, M.B.S. The 2017 World Health Organization classification of tumors of the pituitary gland: A summary. Acta Neuropathol. 2017, 134, 521–535. [Google Scholar] [CrossRef]
- Tan, Z.; Lei, Z.; Yan, Z.; Ji, X.; Chang, X.; Cai, Z.; Lu, L.; Qi, Y.; Yin, X.; Han, X.; et al. Exploiting D2 receptor β-arrestin2-biased signalling to suppress tumour growth of pituitary adenomas. Br. J. Pharmacol. 2021, 178, 3570–3586. [Google Scholar] [CrossRef] [PubMed]
- Gonzalez-Iglesias, A.E.; Murano, T.; Li, S.; Tomić, M.; Stojilkovic, S.S. Dopamine inhibits basal prolactin release in pituitary lactotrophs through pertussis toxin-sensitive and -insensitive signaling pathways. Endocrinology 2008, 149, 1470–1479. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Burris, T.P.; Nguyen, D.N.; Smith, S.G.; Freeman, M.E. The stimulatory and inhibitory effects of dopamine on prolactin secretion involve different G-proteins. Endocrinology 1992, 130, 926–932. [Google Scholar] [PubMed]
- Enjalbert, A.; Bockaert, J. Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary. Mol. Pharmacol. 1983, 23, 576–584. [Google Scholar] [PubMed]
- Cronin, M.J.; Myers, G.A.; MacLeod, R.M.; Hewlett, E.L. Pertussis toxin uncouples dopamine agonist inhibition of prolactin release. Am. J. Physiol. 1983, 244, E499–E504. [Google Scholar] [CrossRef]
- Ågren, R.; Århem, P.; Nilsson, J.; Sahlholm, K. The Beta-Arrestin-Biased Dopamine D2 Receptor Ligand, UNC9994, Is a Partial Agonist at G-Protein-Mediated Potassium Channel Activation. Int. J. Neuropsychopharmacol. 2018, 21, 1102–1108. [Google Scholar] [CrossRef] [Green Version]
- Melkersson, K.; Hulting, A.L. Prolactin-secreting pituitary adenoma in neuroleptic treated patients with psychotic disorder. Eur. Arch. Psychiatry Clin. Neurosci. 2000, 250, 6–10. [Google Scholar] [CrossRef]
- Broekhof, R.; Gosselink, M.J.; Pijl, H.; Giltay, E.J. The effect of aripiprazole and quinagolide, a dopamine agonist, in a patient with symptomatic pituitary prolactinoma and chronic psychosis. Gen. Hosp. Psychiatry 2012, 34, 209.e1–209.e3. [Google Scholar] [CrossRef]
- Chang, S.C.; Chen, C.H.; Lu, M.L. Cabergoline-induced psychotic exacerbation in schizophrenic patients. Gen. Hosp. Psychiatry 2008, 30, 378–380. [Google Scholar] [CrossRef] [PubMed]
- Urs, N.M.; Gee, S.M.; Pack, T.F.; McCorvy, J.D.; Evron, T.; Snyder, J.C.; Yang, X.; Rodriguiz, R.M.; Borrelli, E.; Wetsel, W.C.; et al. Distinct cortical and striatal actions of a β-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties. Proc. Natl. Acad. Sci. USA 2016, 113, E8178–E8186. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pack, T.F.; Orlen, M.I.; Ray, C.; Peterson, S.M.; Caron, M.G. The dopamine D2 receptor can directly recruit and activate GRK2 without G protein activation. J. Biol. Chem. 2018, 293, 6161–6171. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gatto, F.; Feelders, R.; van der Pas, R.; Kros, J.M.; Dogan, F.; van Koetsveld, P.M.; van der Lelij, A.J.; Neggers, S.J.C.M.M.; Minuto, F.; de Herder, W.; et al. Hofland. β-Arrestin 1 and 2 and G Protein-Coupled Receptor Kinase 2 Expression in Pituitary Adenomas: Role in the Regulation of Response to Somatostatin Analogue Treatment in Patients with Acromegaly. Endocrinology 2013, 154, 4715–4725. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Di Muro, G.; Mangili, F.; Esposito, E.; Barbieri, A.M.; Catalano, R.; Treppiedi, D.; Marra, G.; Nozza, E.; Lania, A.G.A.; Ferrante, E.; et al. A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells. Cancers 2023, 15, 3218. https://doi.org/10.3390/cancers15123218
Di Muro G, Mangili F, Esposito E, Barbieri AM, Catalano R, Treppiedi D, Marra G, Nozza E, Lania AGA, Ferrante E, et al. A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells. Cancers. 2023; 15(12):3218. https://doi.org/10.3390/cancers15123218
Chicago/Turabian StyleDi Muro, Genesio, Federica Mangili, Emanuela Esposito, Anna Maria Barbieri, Rosa Catalano, Donatella Treppiedi, Giusy Marra, Emma Nozza, Andrea G. A. Lania, Emanuele Ferrante, and et al. 2023. "A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells" Cancers 15, no. 12: 3218. https://doi.org/10.3390/cancers15123218